Bcl-2 Press Release
|02/10/2020 - 22:09||
Starpharma receives US$3M milestone from AstraZeneca
Melbourne, Australia; 11 February 2020: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received US$3 million (A$4.5 million) from AstraZeneca following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) in December.
|10/01/2019 - 17:14||
A team effort uncovers how cancer outwits a targeted drug
Top, from left: Vivian Liu, Steve Carr, Vamsi Mootha. Bottom, from left: Romain Guièze, Cathy Wu, John Doench.
|09/25/2019 - 19:48||
FDA Authorisation of First-in-Human Clinical Trial with AstraZenecas DEP product AZD0466
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. This is the first DEP® candidate to reach this milestone from Starpharma’s multiproduct license with AstraZeneca.
|08/07/2019 - 19:31||
This combination targeted therapy may offer hope to infants diagnosed with a deadly type of leukemia
DUARTE, Calif. — City of Hope researchers have identified a potential combination targeted therapy for a deadly type of leukemia found in some infants, a population too young to receive full-blown chemotherapy.
|City of Hope Na...|
|06/12/2019 - 06:44||
US patent granted for DEP Bcl2/xL inhibitor conjugates
The first patent for Starpharma’s DEP® dendrimers with AstraZeneca’s Bcl2/xL inhibitors has been granted in the US, with international equivalents to follow This patent provides US exclusivity until 2038, with the potential for up to 5 years’ extension In multiple preclinical cancer models, AstraZeneca’s DEP® Bcl2/xL inhibitor conjugates demonstrate the potential for better anti-cancer activity than Bcl2/xL inhibitor alone, and synergy in combination.
|05/14/2019 - 22:47||
Researchers Pinpoint Why Lymphoma Patients May Become Resistant to Specific Therapy, Identify Strategy to Overcome It
TAMPA, Fla. and BOSTON – With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern. It has often been assumed that drug resistance is due to the presence or development of additional genetic alterations; however, it is now clear that resistance mechanisms are more complicated.
|02/06/2019 - 15:37||
Combination treatment including diabetes drug and immunotherapy may help to fight breast cancer
Researchers in Finland have discovered a drug combination that collaborates with the cancer cells' own MYC oncoprotein, which in large quantities causes self-destruction of the cancer cells.When this combination is enhanced with immune system-boosting anti-PD-1 therapy, a more effective and long-lasting therapeutic effect can be seen in mice. These findings pave the way for new treatment combination strategies to harness the body’s natural defenses to fight cancer.
|12/01/2018 - 09:43||
MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
Voruciclib is currently being evaluated in a Phase 1b dose ranging study in patients with B-cell malignancies.
|11/29/2018 - 19:10||
Venetoclax combination approved for elderly AML
Older patients with acute myeloid leukemia (AML) often aren’t healthy enough to receive intensive chemotherapy, and gentler treatments aren’t very effective in treating this aggressive blood cancer.
|11/01/2018 - 16:44||
MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting
Study investigators will present updated results from the Phase 1b study evaluating ME-401 in relapsed/refractory follicular lymphoma and other indolent B-cell malignancies, as well as results from a preclinical study demonstrating that voruciclib and venetoclax synergistically induce apoptosis in acute myeloid leukemia (AML) cells in vitro.
|08/31/2018 - 06:54||
AstraZenecas DEP Bcl2/xL inhibitors show compelling efficacy and synergy in combination
AstraZeneca’s first of several patent applications on Starpharma’s DEP® dendrimer with AstraZeneca’s Bcl2/xL inhibitors has been published, showing compelling results DEP® Bcl2/xL conjugates demonstrate better anti-cancer activity than Bcl2/xL inhibitor alone in multiple cancer models DEP® Bcl2/xL conjugates in combination with leading current anti-cancer treatments provide substantial improvements in efficacy in multiple leukemia models.
|08/21/2018 - 05:44||
Annual report and full year financial results
Melbourne, Australia; 21 August 2018:Starpharma (ASX: SPL, OTCQX: SPHRY) today released its annual report and financial results for the year ended 30 June 2018.
|08/17/2018 - 09:43||
Tolero Pharmaceuticals announces clinical research collaboration with AbbVie for acute myeloid leukemia trial.
SALT LAKE CITY, August 17, 2018 -- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and oncologic diseases, has entered into a clinical research collaboration with AbbVie, a research-based global biopharmaceutical company, exploring the potential of combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent, alvocidib, for the treatment of relapsed/refractory acute myeloid leukemia (AML).
|05/16/2018 - 18:06||
MEI Pharma to Present Clinical Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, May 16, 2018 / / -- MEI Pharma, Inc. (NASDAQ: MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced the publication of two data abstracts related to MEI Pharma's clinical stage drug development programs to be presented at the 2018 ASCO Annual Meeting to be held June 1-5, 2018 in Chicago. Study investigators will present updated results from the Phase 1b study evaluating ME-401 in relapsed/refractory indolent B-cell malignancies and from an investigator-initiated study of ME-344 in patients with HER2-negative breast cancer.
|12/21/2017 - 08:01||
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
SAN DIEGO, Dec. 21, 2017 / / -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that a study of voruciclib, an orally available CDK9 inhibitor, was published in the journal Nature Scientific Reports. Researchers found that voruciclib when combined with the BCL-2 inhibitor Venclexta™ (venetoclax) was capable of inhibiting two master regulators of drug resistance, MCL-1 and BCL-2, and achieved synergistic antitumor efficacy in an aggressive subset of Diffuse Large B-cell Lymphoma (DLBCL). A phase 1 study of voruciclib in relapsed/refractory B-cell malignancies is planned to begin in the first half of 2018.
|09/05/2017 - 15:17||
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor
SAN DIEGO and SEATTLE, Sept. 5, 2017 / / -- MEI Pharma, Inc.
|06/23/2017 - 04:51||
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers \r Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal deletion \r Preliminary anti-cancer activity seen in phase Ib study of people with acute myeloid leukaemia and multiple myeloma
|04/05/2017 - 08:06||
Tolero Pharmaceuticals presents preclinical data on CDK9 inhibitor alvocidib and its prodrug, TP-1287, at AACR 2017
SALT LAKE CITY, UT --Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, presented preclinical data on alvocidib, an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), in Phase II development for relapsed/refractory acute myeloid leukemia (AML) and its prodrug, TP-1287. The findings were presented during the American Association for Cancer Research (AACR) Annual Meeting, April 1-5, in Washington, D.C.
|04/05/2017 - 06:32||
Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
MENLO PARK, Calif., April 05, 2017 ( ) -- Geron Corporation (Nasdaq:GERN) today announced a poster presentation by Janssen Research & Development, LLC describing non-clinical data on the telomerase inhibitor imetelstat at the 2017 American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 1-5, 2017. The poster presentation is available on Geron’s website at www.geron.com/presentations.
|08/12/2016 - 06:17||
Venetoclax Safe, Shows Promise in Patients With Acute Myelogenous Leukemia
PHILADELPHIA — Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data published in Cancer Discovery, a journal of the American Association for Cancer Research.
|04/12/2016 - 08:51||
Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta™ (venetoclax) for the treatment of people with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. The pivotal study showed a clinically meaningful improvement (overall response rate, ORR) in 80.2 percent of people (95 percent CI 71.3-87.3). Venclexta is the first approved medicine designed to help restore a process in which cells self-destruct (apoptosis) by selectively blocking the BCL-2 protein and is Roche’s tenth new medicine approved in the past seven years.
|03/15/2016 - 14:36||
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
The University of Texas MD Anderson Cancer Center, Houston, Texas.
|01/12/2016 - 17:31||
FDA Grants Priority Review for Venetoclax New Drug Application
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for venetoclax for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion. Venetoclax is a small molecule inhibitor of the BCL-2 protein being developed in partnership with AbbVie, and was granted Breakthrough Therapy Designation by the FDA in April 2015 for the treatment of people with previously treated (relapsed or refractory) CLL with 17p deletion.